CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...
Cancer
BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs
Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...
MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...
CARsgen Therapeutics Gets NMPA Approval for CAR-T Therapy CT011 in Hepatocellular Carcinoma
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from...
Simcere Pharmaceutical Group Gets NMPA Green Light for USP1 Inhibitor SIM0501
Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...
Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment
Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...
Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706
Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...
C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials
C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...
Henlius Biotech Secures Exclusive Rights to Sermonix’s Lasofoxifene for Breast Cancer Treatment in China
Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with...
GenFleet’s SLS009 Receives Fast-Track and Orphan Drug Designations from U.S. FDA for Lymphoma and Leukemia
Shanghai-based biotech GenFleet Therapeutics announced that its CDK9 inhibitor, SLS009 (GFH009), has received fast-track and...
Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration
The US Food and Drug Administration (FDA) has accepted for priority review a filing from...
International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation
The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...
OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study
OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...
Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...
MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...
ShuWen Biotech’s MammaTyper Diagnostic Kit Receives NMPA Approval for Breast Cancer Molecular Classification
ShuWen Biotech Co., Ltd, a biopharmaceutical company based in Zhejiang, has announced that its MammaTyper...
Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments
The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...
CSBIO’s Multi-Kinase Inhibitor CSCJC3456 Gets Green Light for Clinical Trials in Advanced Solid Tumors
Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...
Hengrui Pharmaceuticals Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
MSD Advances Four Oncology Candidates to Late-Stage Trials, Including Partnerships with Kelun-Biotech and Orion
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced significant progress in its oncology pipeline...